Table 3. Treatment regimens.
Characteristics | Overall | Approved n/N (%) | Denied n/N (%) |
Treatment regimen | N = 332 | N = 78 | |
Ledipasvir/Sofosbuvir | 324 | 261/332(78.6%) | 63/78 (80.8%) |
Ledipasvir/Sofosbuvir + Ribavarin | 39 | 30/332 (9.0%) | 9/78 (11.5%) |
Sofosbuvir + Ribavarin | 37 | 33/332 (9.9%) | 4/78 (5.1%) |
Sofosbuvir + Simeprevir | 2 | 1/332 (0.3%) | 1/78 (1.3%) |
3D | 12 | 6/332 (1.8%) | 6/78 (7.7%) |
3D + Ribavarin | 3 | 1/332 (0.3%) | 2/78 (2.6%) |
Abbreviation: 3D, Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir.